Q1 2025 EPS Estimates for Pfizer Inc. (NYSE:PFE) Lifted by Zacks Research

Pfizer Inc. (NYSE:PFEFree Report) – Research analysts at Zacks Research raised their Q1 2025 earnings estimates for Pfizer in a report released on Wednesday, April 10th. Zacks Research analyst K. Shah now anticipates that the biopharmaceutical company will post earnings of $0.59 per share for the quarter, up from their previous forecast of $0.58. The consensus estimate for Pfizer’s current full-year earnings is $2.22 per share. Zacks Research also issued estimates for Pfizer’s Q3 2025 earnings at $0.75 EPS.

Pfizer (NYSE:PFEGet Free Report) last posted its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same quarter last year, the company earned $1.14 EPS. The firm’s revenue for the quarter was down 41.3% on a year-over-year basis.

Several other analysts also recently commented on PFE. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Monday, April 1st. Guggenheim started coverage on Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research note on Thursday, January 4th. Finally, Barclays decreased their price target on Pfizer from $34.00 to $28.00 and set an “equal weight” rating for the company in a research note on Thursday, December 14th. Twelve equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, Pfizer presently has an average rating of “Hold” and a consensus price target of $36.88.

View Our Latest Research Report on PFE

Pfizer Price Performance

Shares of NYSE:PFE opened at $26.34 on Friday. The business has a fifty day moving average price of $27.30 and a 200-day moving average price of $28.98. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The company has a market capitalization of $149.12 billion, a PE ratio of 73.15, a PEG ratio of 1.18 and a beta of 0.61. Pfizer has a 1-year low of $25.61 and a 1-year high of $41.79.

Hedge Funds Weigh In On Pfizer

Several institutional investors have recently made changes to their positions in the business. Fulton Bank N.A. increased its position in Pfizer by 4.7% in the third quarter. Fulton Bank N.A. now owns 176,239 shares of the biopharmaceutical company’s stock worth $5,846,000 after buying an additional 7,991 shares in the last quarter. Portside Wealth Group LLC purchased a new stake in Pfizer in the 2nd quarter worth approximately $2,072,000. Adage Capital Partners GP L.L.C. raised its stake in Pfizer by 40.5% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock worth $157,215,000 after acquiring an additional 1,365,295 shares during the period. Brookstone Capital Management lifted its holdings in Pfizer by 88.5% during the third quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company’s stock valued at $14,109,000 after purchasing an additional 212,369 shares in the last quarter. Finally, ETF Store Inc. boosted its position in shares of Pfizer by 12.0% in the third quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock worth $214,000 after purchasing an additional 727 shares during the period. Institutional investors own 68.36% of the company’s stock.

About Pfizer

(Get Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Stories

Earnings History and Estimates for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.